Doron Therapeutics is a biotechnology company dedicated to developing innovative solutions for osteoarthritis (OA). Their flagship product, MOTYS™, is a Phase 3-ready biologic derived from placental tissue. It leverages a multifaceted mechanism of action, including anti-inflammatory, anti-catabolic, and pro-anabolic effects, offering long-lasting benefits from a single intra-articular injection. MOTYS™ is designed to reduce pain, protect cartilage, and promote tissue regeneration, addressing the unmet need for disease-modifying therapies in OA.

The company originated as a spin-off from Bioventus in 2023, with Bioventus remaining a minority shareholder. MOTYS™ has already demonstrated efficacy in preclinical and clinical studies, showing superior and durable results compared to conventional treatments like hyaluronic acid and steroids. Doron Therapeutics focuses on making MOTYS™ a clinical and commercial success, aiming to transform OA care and improve mobility for millions of patients worldwide.